

THE THIRD NATIONAL AIDS MALIGNANCY CONFERENCE
Natcher Conference Center, National Institutes of Health, Bethesda, Maryland
May 26-27, 1999
Program

May 26

8:00 AM

- 8:00 PM **POSTER PRESENTATIONS**

First Floor Concourse, (Abstract Numbers 22 to 71)

PLENARY LECTURES

Moderators: Dr. Ellen Feigal, *National Cancer Institute*
Dr. Elliot Kieff, *Harvard University*

- 8:30 AM Opening Remarks and Welcome
 Dr. Richard Klausner, *National Cancer Institute*
- 8:45 AM S1 Viral Oncogenesis
 Dr. Harald zur Hausen, *Deutsches Krebsforschungszentrum, Germany*
- 9:10 AM S2 Angiogenesis
 Dr. Isaiah J. Fidler, *MD Anderson Cancer Center*
- 9:35 AM S3 AIDS Malignancies: Innovative Approaches to Therapy
 Dr. James M. Pluda, *National Cancer Institute*
- 10:00 AM Break

10:15 AM

- 12:15 PM **ABSTRACT PRESENTATIONS AIDS Malignancies: Epidemiology and Immunology**

Moderators: Dr. Ashlee V. Moses, *Oregon Health Sciences University*

Dr. Patrick Moore, *Columbia University*

Dr. Thomas O'Brien, *National Cancer Institute*

Dr. Robert Newton, *Imperial Cancer Research Fund, United Kingdom*

- 10:15 AM 1 HIV and Cancer in Adults and Children in Kampala, Uganda
 Dr. Robert Newton, *Imperial Cancer Research Fund, United Kingdom*
- 10:30 AM 2 Kaposi's Sarcoma: Commonest Childhood Malignancy in Zimbabwe
 Dr. Inam Chitsike, *University of Zimbabwe, Zimbabwe*
- 10:45 AM 3 Risk of KS and Other AIDS Defining Diseases in HIV-HHV-8 Coinfected Individuals
 Dr. Giovanni Rezza, *Istituto Superiore di Sanità, Italy*
- 11:00 AM 4 An Improved Approach for the Calibration of a New Enzyme Immunoassay for Human Herpesvirus 8 Antibodies
 Dr. Jeffrey Martin, *University of California, San Francisco*
- 11:15 AM 5 HHV-8 Cellular Immune Responses in Homosexual Men
 Dr. Howard D. Strickler, *Albert Einstein College of Medicine*
- 11:30 AM 6 Identification of a HLA-A 0201 Restricted, Optimal CTL Epitope in the KSHV Kaposin Protein
 Dr. Christian Brander, *AIDS Research Center, Massachusetts General Hospital*
- 11:45 AM 7 Identification of HHV-8 Specific Cytotoxic T Cell Responses
 Dr. Robin A. Weiss, *University College London, United Kingdom*

- 12 NOON 8 MHC Class I Restricted CD8+ Cytotoxic T Lymphocyte Responses to Lytic Proteins of Human Herpesvirus 8
Dr. Charles R. Rinaldo, Jr., *University of Pittsburgh*
- 12:15 PM Lunch Break

PLENARY LECTURES

Moderator: Dr. Joel M. Palefsky, *University of California, San Francisco*

- 1:15 PM S4 Virus Interactions With Immune System
Dr. Hidde Ploegh, *Harvard Medical School*
- 1:40 PM S5 Cell Cycle Control by Human Papillomavirus
Dr. Denise Galloway, *Fred Hutchinson Cancer Research Center*
- 2:05 PM S6 Human Papillomavirus: Cellular Immunology and Viral Vaccines
Dr. John T. Schiller, *National Cancer Institute*
- 2:30 PM Break

2:45 PM

ABSTRACT PRESENTATIONS Papillomavirus Associated Neoplasias and Other Neoplasias

Moderator: Dr. Joel M. Palefsky, *University of California, San Francisco*

- 2:45 PM 9 Malignancy Potential of Small Ruminant Lentiviruses as Analogs to AIDS
Dr. Kalman Perk, *Hebrew University of Jerusalem , Israel*
- 3:00 PM 10 Regulation of Apoptosis by Viruses and Zinc Chelators Antiviral Agents: Implications for Prevention and Therapy of Viral Diseases and Cancer
Dr. J. Albert Fernandez-Pol, *St. Louis University School of Medicine*
- 3:15 PM 11 Clinical and Virological Features of HPV-associated Genital Lesions in HIV-infected Women
Dr. Annarosa Del Mistro, *Azienda Ospedaliera di Padova, Italy*
- 3:30 PM 12 Prevalence and Risks for Cervical Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Adolescent Women: Impact of Infection With HIV
Dr. Anna-Barbara Moscicki, *University of California, San Francisco*
- 3:45 PM 13 The Effect of HAART on the Natural History of Anal Squamous Intraepithelial Lesions in HIV+ Men
Dr. Joel M. Palefsky, *University of California, San Francisco*
- 4:00 PM 14 The Effect of Excisional Therapy and Highly Active Antiretroviral Therapy on Cervical Intraepithelial Neoplasia in HIV Infected Women
Dr. William R. Robinson, *Tulane University School of Medicine*
- 4:15 PM Break

PLENARY LECTURE

Moderator: Dr. Robin Weiss, *University College London, United Kingdom*

- 4:25 PM S7 State-of-the-Art: Human Herpes Virus 8
Dr. Donald Ganem, *University of California, San Francisco*

4:50 PM

- 6:35 PM **ABSTRACT PRESENTATIONS Human Herpesvirus 8**

Moderators: Dr. Ethel Cesarman, *Cornell Medical College*

Dr. Robin Weiss, *University College London, United Kingdom*

Dr. Ashlee V. Moses, *Oregon Health Sciences University*

- 4:50 PM 15 Cellular Tropism and Levels of Viral Gene Expression Distinguish HHV-8 Involvement in Kaposi's Sarcoma, Primary Effusion Lymphoma and Multicentric Castlemann's Disease
Dr. Katherine Staskus, *University of Minnesota*
- 5:05 PM 16 Identification and Characterization of the Two Promoter Elements of the Open Reading Frame 50 of Kaposi's Sarcoma-Associated Herpesvirus
Dr. Shuhong Liu, *University of Nebraska-Lincoln*
- 5:20 PM 17 Post-transcriptional Regulation of KSHV G Protein-coupled Receptor
Dr. Elizabeth Geras-Raaka, *Weill Medical College of Cornell University*
- 5:35 PM 18 The KSHV/HHV-8 G Protein-coupled Receptor Transforms Cells Through Inflammatory-Cytokine Signaling Pathways
Dr. Lic Carlos Bais, *Cornell Medical College*
- 5:50 PM 19 KSHV/HHV-8 Viral MIP-II and RNA Expression in Microvascular Endothelial Cells
Dr. David J. Looney, *University of California, San Diego*
- 6:05 PM 20 V-Cyclin Escapes Ubiquitin-mediated Degradation
Dr. Philip J. Browning, *Vanderbilt University*
- 6:20 PM 21 The Latency-associated Nuclear Antigen Mediates Efficient Persistence of Extrachromosomal KSHV DNA
Dr. Kenneth M. Kaye, *Harvard Medical School*
- 6:35 PM - 7:00 PM Authors at poster
- 6:35 PM - 7:30 PM RECEPTION, First Floor Concourse

May 27

8:00 AM

- 7:30 PM **POSTER PRESENTATIONS**

First Floor Concourse, (Abstract Numbers 94 to 124)

PLENARY LECTURE

Moderator: Dr. Parkash Gill, *University of Southern California School of Medicine*

- 8:30 AM Kaposi's Sarcoma: Where Do We Go From Here?
Dr. Robert Gallo, *Institute of Human Virology*

8:55 AM

- 10:40 AM **ABSTRACT PRESENTATIONS Preclinical Model/Clinical Implications**

Moderators: Dr. Robert Gallo, *Institute of Human Virology*

Dr. Parkash Gill, *University of Southern California School of Medicine*

- 8:55 AM 72 The Distribution of HHV-8 Latently Infected Cells in All Stages of Kaposi's Sarcoma
Dr. Robin A. Weiss, *University College London, United Kingdom*
- 9:10 AM 73 *In Vitro* Infection of Primary Human Keratinocytes by Kaposi's Sarcoma Associated Herpesvirus
Dr. Francesca Cerimele, *Weill Medical College of Cornell University*

- 9:25 AM 74 Creation of Kaposi's Sarcoma (KS)-like Lesions Using HHV-8 Injected Into Engrafted Human Skin on SCID Mice
Dr. Kimberly Foreman, *Loyola University*
- 9:40 AM 75 HHV-8/KSHV Infects Dermal Endothelial Cells and Macrophages: Implications for Kaposi's Sarcoma
Dr. Ashlee V. Moses, *Oregon Health Sciences University*
- 9:55 AM 76 *In Vitro* Inhibition of KSHV/HHV-8 Infected Endothelial Cell Growth by Neutralizing Monoclonal Antibodies to Human VEGFR-2
Sarah Nikolovska, *Weill Medical College of Cornell University*
- 10:10 AM 77 RNA Damage and Inhibition of Kaposi's Sarcoma Cell Growth: Effects of Human vs Amphibian Ribonucleases
Dr. Dianne L. Newton, *National Cancer Institute*
- 10:25 AM 78 Administration of Interleukin 12 to Patients With AIDS-associated Kaposi's Sarcoma: Preliminary Results of a Pilot Study
Dr. James M. Pluda, *National Cancer Institute*

10:40 AM Break

PLENARY LECTURES

Moderator: Dr. Elaine S. Jaffe, *National Cancer Institute*

- 10:55 AM S8 Immune Control in Neoplasia
Dr. Drew M. Pardoll, *Johns Hopkins University*
- 11:20 AM S9 Post-transplant Lymphoproliferative Disease and Implications for AIDS Malignancies
Dr. Lode J. Swinnen, *Loyola University*

11:45 AM Lunch Break

12:45 PM

- 2:15 PM **ABSTRACT PRESENTATIONS Lymphomas and Other Neoplasia: Pathogenesis**

Moderators: Dr. Peter Biberfeld, *Karolinska Institute, Sweden*

Dr. Gianluca Gaidano, "*Amedeo Avogadro*" *University of Eastern Piedmont*

- 12:45 PM 79 An Increased Risk of B-cell Lymphomas in Autoimmune Lymphoproliferative Syndrome
Dr. Elaine S. Jaffe, *National Cancer Institute*
- 1:00 PM 80 A Histogenic Model for Hodgkin's Disease Development in HIV-Positive and HIV-Negative Individuals
Dr. Antonino Carbone, *Centro di Riferimento Oncologico, Italy*
- 1:15 PM 81 Sequential Pathogenesis: A Model Implicating a Role for Clonal Macrophages in Neoplastic and Degenerative HIV Associated Diseases
Dr. Michael S. McGrath, *University of California, San Francisco*
- 1:30 PM 82 Novel Integration Sites in Pediatric Malignancies
Dr. Bruce Shiramizu, *University of Hawaii*
- 1:45 PM 83 Role of Epstein-Barr Virus in the Development of AIDS-related Non-Hodgkin's Lymphoma
Debbie van Baarle, *Sanquin Blood Supply Foundation, The Netherlands*
- 2:00 PM 84 Expression of Epstein Barr Virus Genes in Post-Transplant Lymphoproliferative Disorders
Dr. Elizabeth Hyjek, *Weill Medical College of Cornell University*

PLENARY LECTURE

Moderator: Dr. David T. Scadden, *Harvard Medical School*

2:15 PM S10 Animal Models: Immunodeficiency and Neoplasia
Dr. Peter Biberfeld, *Karolinska Institute, Sweden*

2:40 PM Break

PLENARY LECTURE

Moderator: Dr. David T. Scadden, *Harvard Medical School*

2:55 PM Role of the National Cancer Institute in AIDS-related Drug Discovery
Dr. Edward Sausville, *National Cancer Institute*

3:20 PM

- 5:35 PM **ABSTRACT PRESENTATIONS Lymphomas: Preclinical Models and Clinical Aspects**

Moderators: Dr. Umberto Tirelli, *Centro di Riferimento Oncologico, Italy*
Dr. Peter Biberfeld, *Karolinska Institute, Sweden*

3:20 PM 85 Molecular Profile of Epstein-Barr Virus Infection in AIDS-Related Primary Central Nervous System Lymphoma
Dr. Lucia Fassone, "*Amedeo Avogadro*" *University of Eastern Piedmont*

3:35 PM 86 Combination Antiviral Therapy for Treatment of Primary Central Nervous System Lymphoma Associated With the Epstein Barr Virus: In Vivo Evaluation in an Animal Model
Dr. Michael A. Caligiuri, *Ohio State University*

3:50 PM 87 Antivirals Induce Apoptosis and Tumor Regression in AIDS-related Primary Central Nervous System Lymphoma
Dr. William J. Harrington Jr., *University of Miami School of Medicine*

4:05 PM 88 AIDS Lymphomagenesis Mouse Model
Dr. Elizabeth Zenger, *University of California, San Francisco*

4:20 PM 89 Pathophysiological Role of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Primary Effusion Lymphomas
Dr. Yoshiyasu Aoki, *United States Food and Drug Administration*

4:35 PM 90 Multi-drug Resistance in Newly Diagnosed AIDS-lymphoma
Dr. Anil Tulpule, *University of Southern California School of Medicine*

4: 50 PM 91 Treatment of HIV-related Non-Hodgkin's Lymphoma Adapted to Prognostic Factors
Dr. Umberto Tirelli, *Centro di Riferimento Oncologico, Italy*

5:05 PM 92 Chemotherapy for HIV-associated Non-Hodgkin's Lymphoma in Combination With Highly Active Antiretroviral Therapy is not Associated With Excessive Toxicity
Dr. Lee Ratner, *Washington University*

5:20 PM 93 Dose-Adjusted EPOCH Chemotherapy in Previously Untreated HIV-associated Non-Hodgkin's Lymphoma: Preliminary Report of Efficacy, Immune Reconstitution, and HIV Control Following Therapy
Dr. Richard F. Little, *National Cancer Institute*

5:35 PM - 6:00 PM Authors at poster

5:35 PM - 6:30 PM RECEPTION, First Floor Concourse